– USA, MA – K36 Therapeutics, a biotechnology company, today announced the appointment of Michael Heffernan to its Board as an Independent Director, bringing over 30 years of experience in building and leading development stage and commercial companies in the biopharmaceutical space.
Mr. Heffernan is an advisor, investor, and board member of numerous public and private biopharmaceutical companies. He began his career at Eli Lilly and Company, where he served in numerous sales and marketing roles. He then served in a variety of roles, including President and CEO of Collegium since its inception, co-founder and CEO of Clinical Studies Ltd. (acquired by PhyMatrix Corp), Co-Founder and Chairman/CEO of Avenge Bio, Inc., Chairman/CEO of Onset Dermatologics, and Founder and Chairman of Collegium Pharmaceutical (COLL). He currently is a member of the Board of Directors of Biohaven (BHVN), Collegium (COLL), Trevi (TRVI), and Synlogic (SYBX).
Mr. Heffernan was named E&Y Entrepreneur of the Year, Northeast Regional Winner in 2016. He is a registered pharmacist and earned his B.S. Degree in Pharmacy from the University of Connecticut.
About K36 Therapeutics, Inc.
Founded in February 2021, K36 is a privately held biotech company. Our mission is to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics for the benefit of cancer patients worldwide.
For more information: https://www.k36tx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
